Center Laboratories, Inc. (4123.TWO)
TWD 35.35
(-2.62%)
TWD 35.35
(-2.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -175.17 Million TWD | -206.19% |
| 2022 | 164.95 Million TWD | -84.72% |
| 2021 | 1.07 Billion TWD | 209.14% |
| 2020 | 349.11 Million TWD | 11775.92% |
| 2019 | 381.44 Million TWD | -100.12% |
| 2018 | 10.99 Billion TWD | -3.4% |
| 2017 | 2.69 Billion TWD | 59.43% |
| 2016 | 1.76 Billion TWD | 61.95% |
| 2015 | 1.08 Billion TWD | 52.08% |
| 2014 | 868.68 Million TWD | 307.26% |
| 2013 | 296.11 Million TWD | 486.25% |
| 2012 | 229.52 Million TWD | -207.98% |
| 2011 | 107.61 Million TWD | 34.83% |
| 2010 | 35.95 Million TWD | -36.76% |
| 2009 | 178.03 Million TWD | -45.63% |
| 2008 | 80.96 Million TWD | 10.52% |
| 2007 | 139.66 Million TWD | 42.47% |
| 2006 | 39.18 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 94.59 Million TWD | 101.07% |
| 2024 Q1 | 79.49 Million TWD | -12179.6% |
| 2023 Q2 | -124.87 Million TWD | -183.47% |
| 2023 Q4 | -136.82 Million TWD | -116.93% |
| 2023 Q3 | -63.07 Million TWD | 49.49% |
| 2023 FY | - TWD | -206.19% |
| 2023 Q1 | 149.59 Million TWD | 152.18% |
| 2022 Q3 | 55.59 Million TWD | -72.57% |
| 2022 Q2 | 202.65 Million TWD | 4.79% |
| 2022 Q4 | -286.68 Million TWD | -615.66% |
| 2022 FY | - TWD | -84.72% |
| 2022 Q1 | 193.38 Million TWD | -35.01% |
| 2021 FY | - TWD | 209.14% |
| 2021 Q3 | 222.11 Million TWD | -65.1% |
| 2021 Q4 | 297.56 Million TWD | 33.97% |
| 2021 Q2 | 636.46 Million TWD | 1584.72% |
| 2021 Q1 | -42.86 Million TWD | -203.15% |
| 2020 Q4 | 41.55 Million TWD | 117.66% |
| 2020 Q3 | -235.3 Million TWD | -151.49% |
| 2020 Q2 | 456.97 Million TWD | 422.7% |
| 2020 FY | - TWD | 11775.92% |
| 2020 Q1 | 87.42 Million TWD | 280.5% |
| 2019 FY | - TWD | -100.12% |
| 2019 Q2 | -160.92 Million TWD | -6522.26% |
| 2019 Q3 | 208.79 Million TWD | 229.75% |
| 2019 Q4 | -48.43 Million TWD | -123.2% |
| 2019 Q1 | -2.43 Million TWD | -107.47% |
| 2018 Q2 | 1.01 Billion TWD | 17.98% |
| 2018 FY | - TWD | -3.4% |
| 2018 Q4 | 32.51 Million TWD | -94.05% |
| 2018 Q3 | 546.88 Million TWD | -46.15% |
| 2018 Q1 | 860.75 Million TWD | -6.52% |
| 2017 Q4 | 920.78 Million TWD | 38.37% |
| 2017 FY | - TWD | 59.43% |
| 2017 Q2 | 529.34 Million TWD | 24.13% |
| 2017 Q3 | 665.44 Million TWD | 25.71% |
| 2017 Q1 | 426.43 Million TWD | 17.95% |
| 2016 Q4 | 361.53 Million TWD | -22.86% |
| 2016 FY | - TWD | 61.95% |
| 2016 Q3 | 468.66 Million TWD | 31.14% |
| 2016 Q2 | 357.37 Million TWD | -12.16% |
| 2016 Q1 | 406.87 Million TWD | -58.44% |
| 2015 FY | - TWD | 52.08% |
| 2015 Q1 | -54.76 Million TWD | -111.34% |
| 2015 Q3 | 141.97 Million TWD | 273.95% |
| 2015 Q4 | 978.96 Million TWD | 589.55% |
| 2015 Q2 | -81.61 Million TWD | -49.02% |
| 2014 Q3 | -14.22 Million TWD | -110.72% |
| 2014 FY | - TWD | 307.26% |
| 2014 Q4 | 483.15 Million TWD | 3495.8% |
| 2014 Q2 | 132.76 Million TWD | 190.42% |
| 2014 Q1 | 45.71 Million TWD | -29.41% |
| 2013 Q3 | 124.9 Million TWD | 459.18% |
| 2013 FY | - TWD | 486.25% |
| 2013 Q1 | -3.27 Million TWD | 56.81% |
| 2013 Q2 | -34.77 Million TWD | -960.83% |
| 2013 Q4 | 64.76 Million TWD | -48.15% |
| 2012 Q4 | -7.59 Million TWD | -123.84% |
| 2012 FY | - TWD | -207.98% |
| 2012 Q1 | 2.38 Million TWD | 197.83% |
| 2012 Q2 | -23.5 Million TWD | -1083.97% |
| 2012 Q3 | 31.83 Million TWD | 235.41% |
| 2011 Q3 | 8.57 Million TWD | 165.97% |
| 2011 Q4 | -2.44 Million TWD | -128.48% |
| 2011 FY | - TWD | 34.83% |
| 2011 Q1 | 32.05 Million TWD | 8154.27% |
| 2011 Q2 | 3.22 Million TWD | -89.94% |
| 2010 Q1 | 11.16 Million TWD | 0.0% |
| 2010 Q2 | 13.6 Million TWD | 21.88% |
| 2010 Q4 | -398 Thousand TWD | -110.23% |
| 2010 FY | - TWD | -36.76% |
| 2010 Q3 | 3.89 Million TWD | -71.4% |
| 2009 FY | - TWD | -45.63% |
| 2008 FY | - TWD | 10.52% |
| 2007 FY | - TWD | 42.47% |
| 2006 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Allied Biotech Corporation | 204.79 Million TWD | 185.536% |
| GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 175.8% |
| Easywell Biomedicals, Inc. | -85.5 Million TWD | -104.875% |
| TTY Biopharm Company Limited | 1.52 Billion TWD | 111.491% |
| Synmosa Biopharma Corporation | 1 Billion TWD | 117.365% |
| Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 130.05% |
| Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | 664.191% |
| Orient Pharma Co., Ltd. | 172.39 Million TWD | 201.61% |
| InnoPharmax Inc. | -62.12 Million TWD | -181.986% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | 238.28% |
| Excelsior Biopharma Inc. | -29.36 Million TWD | -496.445% |
| DV Biomed Co., Ltd. | 407.64 Million TWD | 142.972% |
| Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 80.796% |
| Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 121.82% |
| UniPharma Co., Ltd. | -16.25 Million TWD | -977.704% |
| Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 233.402% |
| Alar Pharmaceuticals Inc. | 394.52 Million TWD | 144.401% |
| Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 176.72% |
| Mercury Biopharmaceutical Corporation | -39.03 Million TWD | -348.763% |
| Bioray Biotech Co., Ltd | 12.13 Million TWD | 1543.511% |
| TSH Biopharm Corporation Limited | 99.35 Million TWD | 276.316% |